Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RXRA | P19793 | 6/20 | 0.69 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.55 |
| ▸ | PIM1 | P11309 | 7/20 | 0.54 |
| ▸ | PIM2 | Q9P1W9 | 7/20 | 0.54 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.47 |
| ▸ | PIM3 | Q86V86 | 1/20 | 0.47 |
| ▸ | ESRRA | P11474 | 2/20 | 0.47 |
| ▸ | TTR | P02766 | 1/20 | 0.46 |
| ▸ | CISD1 | Q9NZ45 | 1/20 | 0.46 |
| ▸ | HPGD | P15428 | 2/20 | 0.45 |
| ▸ | NR1H4 | Q96RI1 | 1/20 | 0.44 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.44 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL304434 | 1.00 | RXRA (0.69) | RXRASCN9APIM1PIM2PDE4B | |
| SCHEMBL1619112 | 1.00 | RXRA (0.69) | RXRASCN9APIM1PIM2PDE4B | |
| SCHEMBL7462867 | 0.92 | RXRA (0.59) | RXRASCN9APIM1PIM2PDE4B | |
| SCHEMBL7462864 | 0.92 | RXRA (0.59) | RXRASCN9APIM1PIM2PDE4B | |
| SCHEMBL6450433 | 0.90 | RXRA (0.66) | RXRASCN9APIM1PIM2PDE4B | |
| SCHEMBL6450432 | 0.90 | RXRA (0.66) | RXRASCN9APIM1PIM2PDE4B | |
| SCHEMBL14492768 | 0.90 | RXRA (0.57) | RXRASCN9APIM1PIM2PDE4B | |
| SCHEMBL5484611 | 0.90 | RXRA (0.57) | RXRASCN9APIM1PIM2PDE4B | |
| SCHEMBL5484607 | 0.90 | RXRA (0.57) | RXRASCN9APIM1PIM2PDE4B | |
| SCHEMBL5486526 | 0.89 | RXRA (0.61) | RXRASCN9APIM1PIM2PDE4B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 113 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10604541-B2 | Glucokinase activators and methods of using same | BRISTOL-MYERS SQUIBB COMPANY (US) | 2020-03-31 | — | — | US | disclosed |
| US-20190233449-A1 | GLUCOKINASE ACTIVATORS AND METHODS OF USING SAME | BRISTOL-MYERS SQUIBB COMPANY (US) | 2019-08-01 | — | — | US | disclosed |
| EP-2850073-B1 | PYRIMIDINYLPIPERIDINYLOXYPYRIDONE ANALOGUES AS GPR119 MODULATORS | BRISTOL MYERS SQUIBB CO (US) | 2017-07-19 | — | — | EP | disclosed |
| US-9174965-B2 | Pyrimidinylpiperidinyloxypyridone analogues as GPR119 modulators | BRISTOL-MYERS SQUIBB COMPANY (US) | 2015-11-03 | — | — | US | disclosed |
| EP-2566862-B1 | BENZOFURANYL ANALOGUES AS GPR119 MODULATORS | BRISTOL MYERS SQUIBB CO (US) | 2015-09-16 | — | — | EP | disclosed |
| US-9062028-B2 | Bicyclic nitrogen containing heteroaryl TGR5 receptor modulators | BRISTOL-MYERS SQUIBB COMPANY (US) | 2015-06-23 | — | — | US | disclosed |
| US-20150133479-A1 | PYRIMIDINYLPIPERIDINYLOXYPYRIDONE ANALOGUES AS GPR119 MODULATORS | BRISTOL-MYERS SQUIBB COMPANY | 2015-05-14 | — | — | US | disclosed |
| WO-2015061272-A1 | ISOTOPICALLY LABELED TRIAZOLOPYRIDINE 11-BETA HYDROXYSTEROID DEHYDROGENASE TYPE I INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2015-04-30 | — | — | WO | disclosed |
| EP-2556069-B1 | 4-(1-(PYRIMIDIN-2-YL)PIPERIDIN-4-YLOXY)PYRIDIN-2-ONE COMPOUNDS AS GPR119 MODULATORS | BRISTOL MYERS SQUIBB CO (US) | 2015-04-01 | — | — | EP | disclosed |
| US-20150086504-A1 | POLYMERIC MICROEMULSIONS | JANSSEN PHARMACEUTICA NV (BE) | 2015-03-26 | — | — | US | disclosed |
| WO-2007041112-A2 | DIHYDRO-[1H]-QUINOLIN-2-ONE DERIVATIVES AS RXR AGONISTS FOR THE TREATMENT OF DYSLIPIDEMIA, HYPERCHOLESTEROLEMIA AND DIABETES | JANSSEN PHARMACEUTICA N.V. (BE) | 2007-04-12 | — | — | WO | disclosed |
| US-20070078160-A1 | DIHYDRO-[1H]-QUINOLIN-2-ONE DERIVATIVES AS RXR AGONISTS FOR THE TREATMENT OF DYSLIPIDEMIA, HYPERCHOLESTEROLEMIA AND DIABETES | JANSSEN PHARMACEUTICA N.V. (BE) | 2007-04-05 | — | — | US | disclosed |
| US-20070078160-A1 | DIHYDRO-[1H]-QUINOLIN-2-ONE DERIVATIVES AS RXR AGONISTS FOR THE TREATMENT OF DYSLIPIDEMIA, HYPERCHOLESTEROLEMIA AND DIABETES | JANSSEN PHARMACEUTICA N.V. (BE) | 2007-04-05 | — | — | US | disclosed |
| US-20070078129-A1 | Heterocyclic amide derivatives as RXR agonists for the treatment of dyslipidemia, hypercholesterolemia and diabetes | JANSSEN PHARMACEUTICA N.V. | 2007-04-05 | — | — | US | disclosed |
| US-20070078129-A1 | Heterocyclic amide derivatives as RXR agonists for the treatment of dyslipidemia, hypercholesterolemia and diabetes | JANSSEN PHARMACEUTICA N.V. | 2007-04-05 | — | — | US | disclosed |
| US-7196108-B2 | Bicyclic heterocycles for the treatment of diabetes and other diseases | INCYTE SAN DIEGO INC. (US) | 2007-03-27 | — | — | US | disclosed |
| US-7196108-B2 | Bicyclic heterocycles for the treatment of diabetes and other diseases | INCYTE SAN DIEGO INC. (US) | 2007-03-27 | — | — | US | disclosed |
| US-20060034797-A1 | Polymeric micromulsions | ETHICON INC. | 2006-02-16 | — | — | US | disclosed |
| EP-1504047-A1 | POLYMERIC MICROEMULSIONS | JANSSEN PHARMACEUTICA N.V. (BE) | 2005-02-09 | — | — | EP | disclosed |
| WO-2003093344-A1 | POLYMERIC MICROEMULSIONS | JANSSEN PHARMACEUTICA N.V. (BE) | 2003-11-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10604541-B2 | Glucokinase activators and methods of using same | GCK, GCKR, GALK1 | RXRA 1949/4885SCN9A 1687/4885PIM1 2331/4885 |
| US-20150133479-A1 | PYRIMIDINYLPIPERIDINYLOXYPYRIDONE ANALOGUES AS GPR119 MODULATORS | GPR119, GPR180, GPR139 | RXRA 517/4885SCN9A 904/4885PIM1 3640/4885 |
| US-20070078160-A1 | DIHYDRO-[1H]-QUINOLIN-2-ONE DERIVATIVES AS RXR AGONISTS FOR THE TREATMENT OF DYSLIPIDEMIA, HYPERCHOLESTEROLEMIA AND DIABETES | NR1H2, RXRA, NR1H3 | RXRA 2/4885SCN9A 3685/4885PIM1 4619/4885 |
| US-20190233449-A1 | GLUCOKINASE ACTIVATORS AND METHODS OF USING SAME | GCK, GCKR, GALK1 | RXRA 1949/4885SCN9A 1687/4885PIM1 2331/4885 |
| US-20070078129-A1 | Heterocyclic amide derivatives as RXR agonists for the treatment of dyslipidemia, hypercholesterolemia and diabetes | NR1H2, NR1H3, RXRA | RXRA 3/4885SCN9A 3748/4885PIM1 3942/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.